Company intelligence / Profile preview

Dermasilk Brands

United Kingdom

Ownership: Private
Development stage: Other

Overview

DermaSilk has undergone clinical trials demonstrating effectiveness in reducing itching and scratching associated with sensitive skin conditions, with results comparable to topical steroid cream. The product has been included in multiple European clinical guidelines for atopic eczema, lichen sclerosus, and epidermolysis bullosa management

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Dermasilk Brands.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermasilk Brands.

Explore the full profile